Market Cap
$4.0B
ICUI
ICU MEDICAL INC/DE
$160.84 ▲ +2.33%
Prev close $157.18Market cap$4.0B
ConsensusStrong Buy
12-mo target$193.38 (+20.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)20 New Institutional Positions16 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on ICUI right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$3.3B
Inst. Activity
20 buys / 16 sells
Insider Activity
$0.00 buy / $7.5M sell
Insider Net $
-$7.5M
SEC Reports
6
Price chart 30d -5.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 Event
Sep 3, 2026 SEC DEXTROSE
Unavailable: Product discontinued. This product is distributed by ICU Medical. For questions regardi
Two C-suite insiders at ICU Medical (CFO and VP/General Counsel) sold a combined $1.49M in open-market sales over a 5-da
CLUSTER — Impact 4/10
Sep 3, 2026 Insider
Sanzone Virginia Ruth sold 1,238 shares
VP, General Counsel @ $168.44 ($208.5K)
Sep 3, 2026 Insider
Sanzone Virginia Ruth sold 692 shares
VP, General Counsel @ $171.52 ($118.7K)
Sep 3, 2026 Insider
Sanzone Virginia Ruth sold 724 shares
VP, General Counsel @ $169.53 ($122.7K)
Aug 18, 2026 ftd
Aug 13, 2026 SEC FTD: ICUI — 6,970 shares ($1.3M) failed to deliver
Settlement: 20260818, Price: $182.51, FTD Value: $1,272,094.7, I C U MEDICAL INC
Four ICUI insiders, including the COO and VP-GM of Infusion Capital, sold a total of ~$3.09M in open-market sales over a
CLUSTER — Impact 5/10
Three ICUI insiders sold a total of $2.1M in shares over a 2-day window, led by the COO ($1.6M) and CIO ($401K). While t
CLUSTER — Impact 4/10
Analyst ratings buy % +10.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Aug 7, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 21, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| Jun 15, 2026 | BTIG | INITIATE | Buy | 53% |
| May 27, 2026 | Needham | UPGRADE | Buy | 50% |
| Apr 27, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| Apr 17, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Price targets
Where 8 covering analysts think ICUI trades over the next 12 months.
$193.38 +20.2% upside Strong Buy
Current$160.84 Low$178.00 Median$192.50 High$210.00 8 analysts
$178.00$210.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 3.7/10.
NEUTRALCLUSTER4/10
Two C-suite insiders at ICU Medical (CFO and VP/General Counsel) sold a combined $1.49M in open-mark
Sep 3, 2026
BEARISHCLUSTER5/10
Four ICUI insiders, including the COO and VP-GM of Infusion Capital, sold a total of ~$3.09M in open
Aug 13, 2026
NEUTRALCLUSTER4/10
Three ICUI insiders sold a total of $2.1M in shares over a 2-day window, led by the COO ($1.6M) and
Aug 13, 2026
NEUTRALCLUSTER3/10
Two ICUI insiders — the COO and a director — sold a combined $1.70M in open-market sales on August 1
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 16, 2026
FDA
DEXTROSE
Unavailable: Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. (Disc
Sep 16, 2026
FDA
AMINOSYN-PF
Unavailable: Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. (S
Sep 16, 2026
FDA
AMINOSYN-PF
Unavailable: Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. (S
Sep 1, 2026
FDA
AMINOSYN-PF
Unavailable: Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. (S
Aug 18, 2026
ftd
FTD: ICUI — 6,970 shares ($1.3M) failed to deliver
Settlement: 20260818, Price: $182.51, FTD Value: $1,272,094.7, I C U MEDICAL INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.15 | $2.12–$2.19 | 5.8% | +0.0% | 6↑ 1↓ | $0.6B | 7 |
| Next Q | $2.23 | $2.16–$2.29 | 17.0% | +0.0% | 4↑ 1↓ | $0.6B | 7 |
| Current FY | $8.75 | $8.64–$8.83 | 12.8% | +0.0% | 8↑ 0↓ | $2.2B | 8 |
| Next FY | $9.65 | $9.33–$10.10 | 10.2% | +0.0% | 7↑ 1↓ | $2.3B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.147 | — |
| 7d ago | $2.147 | — |
| 30d ago | $2.147 | — |
| 60d ago | $2.083 | +0.064 |
| 90d ago | $2.080 | +0.067 |
Institutional ownership
Which big funds own ICUI (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.3B total value (22,585,422 shares) as of 2026-Q2. Top holders: BlackRock,, Jupiter, VANGUARD. Net buying activity: 20 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,753,409 | $550.2M | 16.6% | — |
| Jupiter Topco LLC | 2,781,620 | $407.8M | 12.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,470,583 | $215.6M | 6.5% | — |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,298,127 | $190.3M | 5.7% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,123,237 | $164.7M | 5.0% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,053,476 | $154.4M | 4.7% | — |
| STATE STREET CORP | 1,024,369 | $150.2M | 4.5% | — |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 739,138 | $109.3M | 3.3% | — |
| AMERIPRISE FINANCIAL INC | 689,573 | $101.1M | 3.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 660,423 | $96.8M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | ADD | 333,336 | 536,225 | +60.9% | $78.6M |
| GOLDMAN SACHS GROUP INC | ADD | 322,691 | 417,342 | +29.3% | $61.2M |
| MORGAN STANLEY | TRIM | 526,842 | 372,583 | -29.3% | $54.6M |
| TORONTO DOMINION BANK | ADD | 208,932 | 358,023 | +71.4% | $52.5M |
| NORGES BANK | NEW | — | 177,733 | — | $26.1M |
| Point72 Asset Management, L.P. | ADD | 83,167 | 165,469 | +99.0% | $24.3M |
| Quantinno Capital Management LP | TRIM | 215,490 | 158,642 | -26.4% | $23.3M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 243,121 | 148,986 | -38.7% | $21.8M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 79,421 | 58,442 | -26.4% | $8.6M |
| MARSHALL WACE, LLP | ADD | 26,687 | 42,797 | +60.4% | $6.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$7.5M — $0.00 bought, $7.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Sanzone Virginia Ruth | VP, General Counsel | SELL | 1,238 | $168.44 | $208.5K |
| Sep 3, 2026 | Sanzone Virginia Ruth | VP, General Counsel | SELL | 692 | $171.52 | $118.7K |
| Sep 3, 2026 | Sanzone Virginia Ruth | VP, General Counsel | SELL | 724 | $169.53 | $122.7K |
| Sep 3, 2026 | Sanzone Virginia Ruth | VP, General Counsel | SELL | 2,202 | $167.67 | $369.2K |
| Sep 1, 2026 | Bonnell Brian Michael | Chief Financial Officer | SELL | 6,381 | $175.00 | $1.1M |
| Aug 31, 2026 | Bonnell Brian Michael | Chief Financial Officer | SELL | 1,113 | $173.91 | $193.6K |
| Aug 31, 2026 | Bonnell Brian Michael | Chief Financial Officer | SELL | 1,712 | $171.05 | $292.8K |
| Aug 31, 2026 | Bonnell Brian Michael | Chief Financial Officer | SELL | 4,568 | $173.44 | $792.3K |
| Aug 31, 2026 | Bonnell Brian Michael | Chief Financial Officer | SELL | 1,914 | $172.12 | $329.4K |
| Aug 13, 2026 | Woolson Daniel | VP, GM-Infusion Capital | SELL | 5,417 | $181.33 | $982.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ICUI.
Shares short
1,515,688
Settlement Sep 15, 2026
Change vs prior
+5.8%
Semi-monthly cycle
Days to cover
6.3
At avg daily volume
Of shares outstanding
≈6.1%
Estimate — not % of float
All ICUI filing & press-release reports (6)
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportMay 15, 2026
- PRESS-RELEASE reportApr 23, 2026